Project Grant R21AI190985
Award Date
6/20/25
Completion Date
5/31/27
Dollars Obligated
$459K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This federal Project Grant award of $187,938 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The purpose of the grant is to support research that aims to uncover the origin of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA). The grant recipient, The Johns Hopkins University, will use RA-derived monoclonal ACPAs to investigate the hypothesis that ACPAs may arise...
This federal Project Grant award of $527,760.00 was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund research at the University of California, San Francisco (UCSF) to investigate the role of endogenous retroviruses and their superantigens in breaking immune tolerance and driving the autoimmune disease rheumatoid arthritis (RA). The research...
This Project Grant award of $139,895.00 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) will support research into the link between inflammatory arthritis and the development of cardiovascular disease. The key objectives are to investigate whether "trained immunity" - the phenomenon where innate immune cells become reprogrammed to respond more efficiently to a...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) worth $735,372 to Brigham & Women's Hospital Inc. on May 15, 2025. The project, titled "T Cell Expression of Inflammatory Chemokine Receptors," aims to identify transcription factors and cytokines that regulate the expression of chemokine receptors, such as CCR2, CCR5, and CXCR6, on T cells in inflamed...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to investigate the role of Notch signaling in driving synovial fibrogenesis and treatment failure in rheumatoid arthritis (RA). The $529,616 award to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, supports a 5-year research project to: 1)...
This $506,085 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to identify predictive biomarkers for response to biological therapies in patients with rheumatoid arthritis (RA). The primary focus is on evaluating the potential of obesity-induced inflammatory mediators, including proteins (adipokines) and lipids, to predict...
This Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to investigate the role of reverse transendothelial migration of neutrophils in inflammation resolution. The $366,797 award, with a project period from Sep 24, 2024 to Aug 31, 2026, aims to provide new insights into the mechanisms by which certain inflammatory mediators,...
This federal Project Grant award, funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to develop a novel joint-targeted antibody therapy for the treatment of rheumatoid arthritis (RA). The award, totaling $402,086, will support the research team's efforts to synthesize new collagen hybridizing peptide (CHP) structures with high affinity to denatured collagen, and to...
This federal Project Grant award, valued at $828,682 and awarded on September 24, 2024, supports research into population-based outcomes for rheumatoid arthritis (RA) in rural health settings. The funding is provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The research aims to investigate the challenges rural residents face in timely RA diagnosis and treatment...
This $548,828 Project Grant was awarded on September 21, 2023 by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant was awarded to Knoubis Bio Inc., a for-profit organization based in California, to support research on a non-immunosuppressive disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis. The project aims to develop a new therapeutic approach...